Antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2
The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
1. An antibody capable of binding to the spike protein of coronavirus SARS-CoV-2, wherein the antibody comprises: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 955, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 956, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 957, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 958, a CDRL2 comprising the amino acid sequence EVS, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 960, wherein the antibody comprises a M252Y/S254T/T256E(YTE) mutation according to IMGT numbering.
2. The antibody of claim 1 , wherein the antibody comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 952 and a light chain variable domain comprising the sequence of SEQ ID NO: 954.
3. The antibody of claim 1 , wherein the antibody comprises an Fc region.
4. The antibody of claim 2 , wherein the antibody comprises an IgG1 constant region.
5. A polynucleotide encoding the light chain variable region and/or heavy chain variable region of the antibody of claim 2 .
6. A vector comprising one or more polynucleotides of claim 5 .
7. A host cell comprising a polynucleotide encoding the light variable region of the antibody of claim 2 and a polynucleotide encoding the heavy chain variable region of the antibody of claim 2 .
8. A method for producing an antibody that is capable of binding to the spike protein of coronavirus SARS-CoV-2, comprising culturing the host cell of claim 7 and isolating the antibody from said culture.
9. A pharmaceutical composition comprising:
(a) the antibody of claim 1 , and
(b) at least one pharmaceutically acceptable diluent or carrier.
10. A pharmaceutical composition comprising:
(a) the antibody of claim 4 , and
(b) at least one pharmaceutically acceptable diluent or carrier.
11. A method of treating a disease or complication associated with SARS-CoV-2 infection, comprising administering a therapeutically effective amount of an antibody capable of binding to the spike protein of coronavirus SARS-CoV-2, wherein the antibody comprises: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 955, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 956, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 957, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 958, a CDRL2 comprising the amino acid sequence EVS, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 960.
12. The method of claim 11 , wherein antibody comprises a heavy chain variable domain comprising the sequence of SEQ ID NO: 952 and a light chain variable domain comprising the sequence of SEQ ID NO: 954.
13. The method of claim 12 , wherein the antibody comprises an IgG1 constant region.
14. The method of claim 13 , wherein the antibody comprises a M252Y/S254T/T256E(YTE) mutation according to IMGT numbering.
15. The method of claim 11 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the lineage alpha, beta, gamma, or delta.
16. The method of claim 11 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the omicron lineage, and wherein the omicron strain is Omicron BA.1, Omicron BA.1.1, Omicron BA.2, and/or Omicron BA.3.
17. A method of identifying the presence of SARS-CoV-2, or a protein fragment thereof, in a sample, comprising: contacting the sample with an antibody capable of binding to the spike protein of coronavirus SARS-CoV-2 and detecting the presence or absence of an antibody-antigen complex wherein the presence of the antibody-antigen complex indicates the presence of SARS-CoV-2, or a fragment thereof, in the sample, wherein the antibody comprises: a CDRH1 comprising the amino acid sequence of SEQ ID NO: 955, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 956, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 957, a CDRL1 comprising the amino acid sequence of SEQ ID NO: 958, a CDRL2 comprising the amino acid sequence EVS, and a CDRL3 comprising the amino acid sequence of SEQ ID NO: 960.
18. The method of claim 12 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the lineage alpha, beta, gamma, or delta.
19. The method of claim 12 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the omicron lineage, and wherein the omicron strain is Omicron BA.1, Omicron BA.1.1, Omicron BA.2, and/or Omicron BA.3.
20. The method of claim 13 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the lineage alpha, beta, gamma, or delta.
21. The method of claim 13 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the omicron lineage, and wherein the omicron strain is Omicron BA.1, Omicron BA.1.1, Omicron BA.2, and/or Omicron BA.3.
22. The method of claim 14 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the lineage alpha, beta, gamma, or delta.
23. The method of claim 14 , wherein the SARS-CoV-2 infection is caused by a SARS-CoV-2 strain of the omicron lineage, and wherein the omicron strain is Omicron BA.1, Omicron BA.1.1, Omicron BA.2, and/or Omicron BA.3.
24. A pharmaceutical composition comprising:
(a) the antibody of claim 2 , and
(b) at least one pharmaceutically acceptable diluent or carrier.
25. The method of claim 11 , wherein the antibody is administered in a pharmaceutical composition comprising (a) the antibody, and (b) at least one pharmaceutically acceptable diluent or carrier.
26. The method of claim 12 , wherein the antibody is administered in a pharmaceutical comprising (a) the antibody, and
(b) at least one pharmaceutically acceptable diluent or carrier.